Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.

Stephen C BainOfri MosenzonRosario ArechavaletaPawel BogdańskiAbdurrahman ComlekciAgostino ConsoliChaicharn DeerochanawongKathleen M DunganMaria C FaingoldMichael E FarkouhDenise R FrancoJeppe GramCristian GujaPankaj JoshiRachid MalekJuan F Merino-TorresMichael A NauckSue D PedersenWayne H-H SheuRobert J SilverCees J TackNikhil TandonOle K JeppesenMette StrangeMette ThomsenMansoor Husain

Published in: Diabetes, obesity & metabolism (2018)

PIONEER 6 will provide evidence regarding the CV safety of oral semaglutide in patients with type 2 diabetes and high CV risk.

Keyphrases

clinical trial
study protocol
phase iii
open label